Chief Executive Officer Provectus Pharmaceuticals Inc

Both of these goals were successfully met,and Provectus is in a position for a Phase 2 study of PV-10 for recurrent breastcancer.DERMATOLOGY- PH-10 FOR ATOPIC DERMATITIS: In May Provectus Began a Phase 2 Clinical Trial of PH-10, a TopicalFormulation of Rose Bengal for Dermatology, for Atopic Dermatitis. The study isevaluating safety and efficacy of PH-10 in a total of twenty subjects with mildto severe forms of the disease. The daily application of the drug in the studywill also provide relevant information for the treatment of other dermatologicconditions, including psoriasis and infectious diseases of the skin, includingantibiotic resistant Staphylococcus aureus (MRSA), a growing public healthconcern. The study is being conducted at International Dermatology Research Inc.of Miami, Florida.DEEPENED PATENT PORTFOLIO: Our Patent Portfolio was Expanded During The Year and now Includes 23 U.S.Patents and 29 Foreign Issued Patents.

We received patents and patent allowancesin several different countries this year, including India, the U.S., Europe andChina, covering PV-10, PH-10 and a related novel agent PH-12.FINANCIAL- AMPLE FUNDING FOR CLINICAL TRIALS: We Received Approximately $2.6 Million From the Conversion of OutstandingWarrants, Providing Additional Cash to Fund Operations. We have spentapproximately $4.5 million on R & D, with an additional $1.5 million slated inour budget. We believe we have ample cash on hand to complete the development ofour current trials-PV-10 Phase 2 for Metastatic Melanoma; PH-10 Phase 2 forPsoriasis and Atopic Dermatitis, Phase 1 for liver cancer, as well as otherdevelopment activities.CORPORATE- EXPANDED BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD; NEWINVESTOR PRESENTATION ON WEBSITE: We Added More Depth to our Boards, with the Appointment of Kelly M. McMastersMD, Ph.D., a preeminent authority on melanoma to serve on our Board of Directorsand to also head our scientific advisory board The addition of Dr. The presentation nowincludes comparisons of Provectus to other companies in its peer group as wellas the dates that it expects to announce preliminary results of the PV-10 Phase2 clinical trial. The updated presentation can be found at the following link onthe company's website: http:// appreciate the contributions made by our corporate team as well as our teamof investigators, as we continue to advance our mission of improving theprognosis for patients with critical or chronic diseases.

2008 was an extremelybusy and productive year, one in which we made great progress. We look forwardto the opportunities that 2009 will bring to us, and thank our shareholders fortheir continued support. Respectfully,Craig Dees, Ph.D.Chief Executive Officer, Provectus Pharmaceuticals, Inc.About Provectus Pharmaceuticals, Inc. ()Provectus Pharmaceuticals is a development stage company that specializes inoncology and dermatology therapies that are safer, more effective, less invasiveand more economical than conventional therapies. Provectus is currentlyconducting Phase 2 clinical trials of its proprietary drugs PV-10 as a therapyfor metastatic melanoma and PH-10 as a topical treatment for psoriasis andatopic dermatitis. Information about these and the Companys other clinicaltrials can be found at the NIH registry, The Company hasreceived orphan drug designation from the FDA for its melanoma indication.Complementing their suite of proprietary drugs, Provectus has developed a numberof intellectual properties and technologies in the areas of imaging, medicaldevices and biotechnology. For additional information about Provectus pleasevisit the Company's website at or contact Porter, LeVay & Rose,Inc.